Navigation Links
Penn Medicine researcher receives $6 million grant for cardiovascular disease study
Date:1/3/2011

(PHILADELPHIA) An international team of researchers led by Daniel J. Rader, MD, associate director of Penn Medicine's Institute for Translational Medicine and Therapeutics, has received a $6 million grant from the Paris-based Fondation Leducq to study the molecular genetics of atherosclerotic cardiovascular disease. The team's proposal, "Molecular Mechanisms of Novel Genes Associated with Plasma Lipids and Cardiovascular Disease," was selected to receive the award through the Fondation's Transatlantic Networks of Excellence Program.

The investigation will focus on determining the molecular mechanisms of some of the most compelling genes to come out of genome-wide association studies (GWAS) for coronary heart disease and heart attack. Specifically, the research team will study six novel genes found by GWAS to be associated with heart disease in order to rigorously assess their function in physiological processes associated with cardiovascular disease and whether or not they are viable targets for future therapeutic developments.

The multidisciplinary, international research team includes experts in epidemiology, human genetics, molecular and cell biology, and animal physiology. In addition to identifying new potential therapeutic targets, this research program will also establish an infrastructure for the systematic evaluation of future GWAS results in the area of cardiovascular disease.

The award is funded through the Fondation Leducq's Transatlantic Networks of Excellence Program. Each research network receives $6 million over five years to support a collaborative research program involving European and North American investigators.

In addition to Rader, other scientists involved in the study include:

European Coordinator: Christian Weber, MD, RWTH, Aachen University, Germany

Members: Endre Kiss-Toth, PhD, University of Sheffield, United Kingdom; Thomas Quertermous, MD, Stanford Cardiovascular Medicine, US; Sekar Kathiresan, MD, Harvard Medical School and Massachusetts General Hospital, US; Mason Freeman, MD, Massachusetts General Hospital, US; Heiko Runz, MD, University of Heidelberg, Germany; Rainer Pepperkok, PhD, European Molecular Biology Laboratory, Germany; John Danesh, PhD, University of Cambridge, United Kingdom; Robert Hegele, MD, University of Western Ontario, Canada; Ronald Krauss, MD, University of California, Berkeley, US; Marju Orho-Melander, MD, Lund University, Sweden; and Ira Tabas, MD, PhD, Columbia University, US.

The Fondation Leducq, a Paris-based nonprofit institution, is dedicated to improving human health through international efforts to combat cardiovascular disease.


'/>"/>

Contact: Jessica Mikulski
jessica.mikulski@uphs.upenn.edu
215-349-8369
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. New way to make malaria medicine also first step in finding new antibiotics
2. Where optics meets medicine
3. Salk researcher Terry Sejnowski elected to Institute of Medicine
4. Innovations in Pediatric Medicine CME conference brings together national pediatrics experts
5. Rutgers scholar authors definitive biography of reproductive medicine pioneer
6. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
7. Researchers at UH explore patient preferences for personalized medicine
8. Innovations in Pediatric Medicine International Conference brings together pediatrics experts
9. Personalized medicine: Innovative online journal leads the way
10. The next step in health care: Telemedicine
11. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided for the ... for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
(Date:2/16/2017)... ... 16, 2017 , ... EIT Digital has launched work to develop ... Pilot studies are about to get under way for the framework, which is designed ... The concept is expected to be transferred eventually to other industries that also require ...
Breaking Biology Technology: